In CKD-associated mineral bone disorder, which laboratory abnormalities drive secondary hyperparathyroidism?

• A. Hyperphosphatemia, hypocalcemia, and low active vitamin D levels.
• B. Hypophosphatemia, hypercalcemia, and high active vitamin D levels.
• C. Hyperphosphatemia, hypercalcemia, and high active vitamin D levels.
• D. Normal phosphate, normal calcium, and normal vitamin D levels.

Answer: (A)

In CKD-associated mineral bone disorder, the kidney’s reduced ability to excrete phosphate and to activate vitamin D drives secondary hyperparathyroidism. Phosphate retention leads to hyperphosphatemia, which lowers free calcium levels and, together with impaired kidney function, reduces production of active vitamin D (1,25-dihydroxyvitamin D). Less active vitamin D means decreased intestinal calcium absorption, contributing to hypocalcemia. The drop in calcium stimulates the parathyroid glands to secrete more PTH, causing secondary hyperparathyroidism. So the lab pattern that drives this process is high phosphate, low calcium, and low active vitamin D. The other patterns—low phosphate with high calcium and high vitamin D, or normal labs—do not provoke the same PTH response in CKD.